Jamie Kang

[British Journal of Cancer] ATGL-mediated lipolysis represents a promising therapeutic target in prostate cancer, with heightened sensitivity in tumours lacking metabolic flexibility to utilize alternative pathways.

[Oncogene] Researchers showed that the rRNA m6A methyltransferase METTL5 was progressively upregulated during prostate cancer progression and was associated with poor patient survival.

[Cancer Science] Scientists revealed that the nuclear receptor subfamily 3 group C member 1 (NR3C1)-acyl-CoA synthetase long-chain family member 4 (ACSL4) axis regulates lipid peroxidation and promotes radioresistance.

[Journal of Medicinal Chemistry] The authors highlight that PSMA-targeting agents incorporate the O-(carboxymethyl)-L-tyrosine scaffold, a versatile linker that enhances binding affinity and optimizes pharmacokinetics.

[Pfizer, Inc.] Pfizer, Inc. announced that the US FDA accepted for Priority Review a supplemental New Drug Application for TALZENNA^®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI^®, an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer.

[Cell Stem Cell] Researchers developed a drug-inducible phase-separation CAR system utilizing FDA-approved fulvestrant and an engineered estrogen receptor α mutant as the drug-inducible phase-separation module.